Floatz logo

Bendamustine

Recurrent Primary Peritoneal Carcinosarcoma

Mayo ClinicSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Recurrent Primary Peritoneal Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Mayo Clinic
Phase 1/2CCC
Pembrolizumab
Mayo Clinic
Phase 1/2CC
Irinotecan
National Cancer Institute (NCI)
Phase 1/2CC
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 1/2CC
Epirubicin
Mayo Clinic
Phase 1/2CC

View all 9 →

Same molecule, other indications

Bendamustine is also rated in:

mantle cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →